At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, Published online: 13 January 2023; doi:10.1038/s41571-022-00718-xImmune-checkpoint inhibitors (ICI) constitute a paradigm shift in the treatment of non-small-cell lung cancer (NSCLC); however, identifying the minority of patients who derive long-term benefit remains problematic, particularly among those with targetable oncogenic drivers who have typically been under-represented in or excluded from clinical trials of ICIs. This Review summarizes the associations of common oncogenic drivers of NSCLC with sensitivity or resistance to ICIs as well as the underlying effects on the immune tumour microenvironment. Potential vulnerabilities that could potentially be exploited to overcome primary resistance to ICIs conferred by certain oncogenic drivers are also highlighted.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Itziar Otano Alvaro C. Ucero Jon Zugazagoitia Luis Paz-Ares Source Type: research
More News: Addiction | Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer